PipelineReview.com9h
Otsuka Announces Positive Interim Results from the Phase 3 Trial of Sibeprenlimab for the Treatment of Immunoglobulin A Nephropathy in Adults
PRINCETON, NJ, USA & TOKYO, Japan I2, 2024 I Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical, Co. Ltd.
PipelineReview.com6h
SIGA Enters into Exclusive License Agreement with Vanderbilt University for Novel Poxvirus Monoclonal Antibodies
NEW YORK, NY, USA I October 22, 2024 I SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company and leader in infectious diseases, today announced that it entered into ...
PipelineReview.com8h
First participants enrolled in first-in-human Phase I clinical trial with nociceptin (NOP) receptor agonist
AACHEN, Germany I October 22, 2024 I Today, Grünenthal announced that the first participants have been enrolled in a first-in-human Phase I clinical trial for ...
PipelineReview.com9h
MacroGenics Enters Into Agreement With TerSera Therapeutics for the Sale of MARGENZA®
ROCKVILLE, MD & DEERFIELD, IL, USA I2, 2024 I MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, ...
PipelineReview.com1d
REGENXBIO Presents Positive Data from the Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD at AAO 2024
ROCKVILLE, MD, USA I October 21, 2024 I REGENXBIO Inc. (Nasdaq: RGNX) today announced positive data from the Phase II fellow eye sub-study evaluating the ...
PipelineReview.com1d
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers
VANCOUVER, Canada I1, 2024 I Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, ...
PipelineReview.com1d
Find Therapeutics Announces First Subject Dosed in Phase 1 Clinical Study of FTX-101
MONTREAL, Canada I1, 2024 I Find Therapeutics Inc., a clinical-stage biopharmaceutical company focused on the development of innovative therapies ...
PipelineReview.com3d
Genentech’s Vabysmo Improved Vision in Underrepresented Populations With Diabetic Macular Edema (DME) in a First-Of-Its-Kind Study
The ELEVATUM study showed clinically meaningful improvement in vision and reduction in retinal fluid in people with DME ...
PipelineReview.com5d
SciRhom Initiates Dosing in First-in-Man Clinical Study Evaluating theCompany’s Lead Development Program SR-878
Transition into clinical-stage development marks a significant corporate and R&D milestone.
PipelineReview.com4d
Chengdu Baiyu enters into a license agreement for the development and commercialization of its Anti-tumor small molecule inhibitor
CHENGDU, China I October16, 2024 I Chengdu Baiyu Pharmaceutical Co., Ltd. ("Baiyu") today announced that it has entered into an exclusive license ...
PipelineReview.com7d
IsomAb Announces Nomination of Development Candidate for Peripheral Arterial Disease and Strategic Collaboration with Pfizer
ISM-001 is a potential first-in-class antibody that may lead to a new treatment pathway for patients with peripheral arterial ...
PipelineReview.com3d
Astellas’ VYLOY™ (zolbetuximab-clzb) Approved by U.S. FDA for Treatment of Advanced Gastric and GEJ Cancer
VYLOY is the first and only CLDN18.2-targeted treatment approved in the U.S. for adults with advanced gastric and gastroesophageal junction cancer whose tumors are CLDN18.2 positive TOKYO, Japan I ...